Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes

Eric Padron; Markus C. Ball; Jamie K. Teer; Jeffrey S. Painter; Sean J. Yoder; Chaomei Zhang; Ling Zhang; Lynn C. Moscinski; Dana E. Rollison; Steven D. Gore; Rafael Bejar; Matthew J. Walter; Mikkael A. Sekeres; Rami S. Komrokji; Pearlie K. Epling-Burnette

doi:10.1182/blood-2018-01-827881

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes

Eric Padron
, Markus C. Ball
, Jamie K. Teer
, Jeffrey S. Painter
, Sean J. Yoder
, Chaomei Zhang
, Ling Zhang
, Lynn C. Moscinski
, Dana E. Rollison
, Steven D. Gore
, Rafael Bejar
, Matthew J. Walter
, Mikkael A. Sekeres
, Rami S. Komrokji
, Pearlie K. Epling-Burnette

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2402-2405
Number of pages	4
Journal	Blood
Volume	131
Issue number	21
DOIs	https://doi.org/10.1182/blood-2018-01-827881
State	Published - May 24 2018

Access to Document

10.1182/blood-2018-01-827881

Cite this

Padron, E., Ball, M. C., Teer, J. K., Painter, J. S., Yoder, S. J., Zhang, C., Zhang, L., Moscinski, L. C., Rollison, D. E., Gore, S. D., Bejar, R., Walter, M. J., Sekeres, M. A., Komrokji, R. S., & Epling-Burnette, P. K. (2018). Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood, 131(21), 2402-2405. https://doi.org/10.1182/blood-2018-01-827881

@article{d76fdbab09f44ce1a828c8510af2719a,

title = "Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes",

author = "Eric Padron and Ball, \{Markus C.\} and Teer, \{Jamie K.\} and Painter, \{Jeffrey S.\} and Yoder, \{Sean J.\} and Chaomei Zhang and Ling Zhang and Moscinski, \{Lynn C.\} and Rollison, \{Dana E.\} and Gore, \{Steven D.\} and Rafael Bejar and Walter, \{Matthew J.\} and Sekeres, \{Mikkael A.\} and Komrokji, \{Rami S.\} and Epling-Burnette, \{Pearlie K.\}",

note = "Funding Information: This work was supported by the National Institutes of Health, National Heart Lung and Blood Institute (NHLBI) contracts HHSN268201400003I and HHSN268201400002I as part of The National MDS Study (https:// thenationalmdsstudy.net/), a collaboration between the NHLBI and the National Cancer Institute (NCI) being conducted in clinical sites that participate in NCI{\textquoteright}s National Clinical Trials Network and the NCI Community Oncology Research Program, and by Shared Resources, including the Tissue Core and Genomics and Bioinformatics Core at the H. Lee Moffitt Cancer Center \& Research Institute, an NCI-designated Comprehensive Cancer Center (P30-CA076292). Funding Information: The authors thank the individual members of the Protocol Writing Team and Steering Committee for their valuable contributions to The National MDS Study and for their help preparing this manuscript. This work was supported by the National Institutes of Health, National Heart Lung and Blood Institute (NHLBI) contracts HHSN268201400003I and HHSN268201400002I as part of The National MDS Study (https://thenationalmdsstudy.net/), a collaboration between the NHLBI and the National Cancer Institute (NCI) being conducted in clinical sites that participate in NCI?s National Clinical Trials Network and the NCI Community Oncology Research Program, and by Shared Resources, including the Tissue Core and Genomics and Bioinformatics Core at the H. Lee Moffitt Cancer Center \& Research Institute, an NCI-designated Comprehensive Cancer Center (P30-CA076292). Funding Information: The authors thank the individual members of the Protocol Writing Team and Steering Committee for their valuable contributions to The National MDS Study and for their help preparing this manuscript. This work was supported by the National Institutes of Health, National Heart Lung and Blood Institute (NHLBI) contracts HHSN268201400003I and HHSN268201400002I as part of The National MDS Study (https://thenationalmdsstudy.net/), a collaboration between the NHLBI and the National Cancer Institute (NCI) being conducted in clinical sites that participate in NCI{\textquoteright}s National Clinical Trials Network and the NCI Community Oncology Research Program, and by Shared Resources, including the Tissue Core and Genomics and Bioinformatics Core at the H. Lee Moffitt Cancer Center \& Research Institute, an NCI-designated Comprehensive Cancer Center (P30-CA076292).",

year = "2018",

month = may,

day = "24",

doi = "10.1182/blood-2018-01-827881",

language = "English",

volume = "131",

pages = "2402--2405",

journal = "Blood",

issn = "0006-4971",

number = "21",

}

TY - JOUR

T1 - Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes

AU - Padron, Eric

AU - Ball, Markus C.

AU - Teer, Jamie K.

AU - Painter, Jeffrey S.

AU - Yoder, Sean J.

AU - Zhang, Chaomei

AU - Zhang, Ling

AU - Moscinski, Lynn C.

AU - Rollison, Dana E.

AU - Gore, Steven D.

AU - Bejar, Rafael

AU - Walter, Matthew J.

AU - Sekeres, Mikkael A.

AU - Komrokji, Rami S.

AU - Epling-Burnette, Pearlie K.

N1 - Funding Information: This work was supported by the National Institutes of Health, National Heart Lung and Blood Institute (NHLBI) contracts HHSN268201400003I and HHSN268201400002I as part of The National MDS Study (https:// thenationalmdsstudy.net/), a collaboration between the NHLBI and the National Cancer Institute (NCI) being conducted in clinical sites that participate in NCI’s National Clinical Trials Network and the NCI Community Oncology Research Program, and by Shared Resources, including the Tissue Core and Genomics and Bioinformatics Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center (P30-CA076292). Funding Information: The authors thank the individual members of the Protocol Writing Team and Steering Committee for their valuable contributions to The National MDS Study and for their help preparing this manuscript. This work was supported by the National Institutes of Health, National Heart Lung and Blood Institute (NHLBI) contracts HHSN268201400003I and HHSN268201400002I as part of The National MDS Study (https://thenationalmdsstudy.net/), a collaboration between the NHLBI and the National Cancer Institute (NCI) being conducted in clinical sites that participate in NCI?s National Clinical Trials Network and the NCI Community Oncology Research Program, and by Shared Resources, including the Tissue Core and Genomics and Bioinformatics Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center (P30-CA076292). Funding Information: The authors thank the individual members of the Protocol Writing Team and Steering Committee for their valuable contributions to The National MDS Study and for their help preparing this manuscript. This work was supported by the National Institutes of Health, National Heart Lung and Blood Institute (NHLBI) contracts HHSN268201400003I and HHSN268201400002I as part of The National MDS Study (https://thenationalmdsstudy.net/), a collaboration between the NHLBI and the National Cancer Institute (NCI) being conducted in clinical sites that participate in NCI’s National Clinical Trials Network and the NCI Community Oncology Research Program, and by Shared Resources, including the Tissue Core and Genomics and Bioinformatics Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center (P30-CA076292).

PY - 2018/5/24

Y1 - 2018/5/24

UR - https://www.scopus.com/pages/publications/85047883349

U2 - 10.1182/blood-2018-01-827881

DO - 10.1182/blood-2018-01-827881

M3 - Letter

C2 - 29661788

AN - SCOPUS:85047883349

SN - 0006-4971

VL - 131

SP - 2402

EP - 2405

JO - Blood

JF - Blood

IS - 21

ER -

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes

Access to Document

Other files and links

Cite this